Targeted therapies in the treatment of advanced hepatocellular carcinoma. by Wei, Zhengyu et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Surgery Faculty Papers Department of Surgery
1-1-2013
Targeted therapies in the treatment of advanced
hepatocellular carcinoma.
Zhengyu Wei
Cooper University Hospital and Cooper Medical School of Rowan University, Camden, NJ
Cataldo Doria
Jefferson Medical College - Thomas Jefferson University Hospital, cataldo.doria@jefferson.edu
Yuan Liu
Cooper University Hospital and Cooper Medical School of Rowan University, Camden, NJ
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/surgeryfp
Part of the Surgery Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Surgery Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Wei, Zhengyu; Doria, Cataldo; and Liu, Yuan, "Targeted therapies in the treatment of advanced
hepatocellular carcinoma." (2013). Department of Surgery Faculty Papers. Paper 88.
http://jdc.jefferson.edu/surgeryfp/88
Clinical Medicine Insights: Oncology 2013:7 87–102
doi: 10.4137/CMO.S7633
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article published under the Creative Commons CC-BY-NC 3.0 license.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Clinical Medicine Insights: Oncology
R e v I e w
Clinical Medicine Insights: Oncology 2013:7 87
Targeted Therapies in the Treatment of Advanced 
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Abstract: Hepatocellular carcinoma (HCC) is the most common liver cancer and the third leading cause of cancer death. It has been 
a major worldwide health problem with more new cases being diagnosed each year. The current available therapies for patients with 
advanced HCC are extremely limited. Therefore, it is of great clinical interests to develop more effective therapies for systemic treatment 
of advanced HCC. Several promising target-based drugs have been tested in a number of clinical trials. One breakthrough of these efforts 
is the approved clinical use of sorafenib in patients with advanced HCC. Targeted therapies are becoming an attractive option for the treat-
ment of advanced HCC. In this review, we summarize the most recent progress in clinical targeted treatments of advanced HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the most com-
mon liver cancer and the third leading cause of can-
cer death. It has been one of the major global health 
problems with increasing new cases coming up each 
year. The major risk factors for HCC development are 
hepatitis B and C viral infections, which lead to liver 
cirrhosis and account for 75% of HCC cases.1,2 Other 
etiologic factors include toxic chemical exposure, 
alcohol abuse, and intake of aflatoxin-contaminated 
food.3,4 HCC has long been a major disease in devel-
oping countries, with most cases occurring in Eastern 
Asia and sub-Saharan Africa; however, there is a ris-
ing incidence in Western countries and many emerg-
ing cases are associated with hepatitis C infection, 
obesity/type 2 diabetes, and nonalcoholic fatty liver 
disease (NAFLD) such as nonalcoholic steatohepa-
titis (NASH).5,6 The worldwide incidence of HCC is 
over 600,000 cases every year.7,8
Treatment of HCC is most effective in the early 
stages. If diagnosed early, major treatment options 
are surgery and interventional radiological therapy. 
Surgical options include surgical resection, cryo-
surgery, radiofrequency ablation (RFA), and liver 
transplantation, while interventional radiological 
therapy includes hepatic artery chemoembolization, 
percutaneous ethanol injection, percutaneous radio 
frequency ablation, and cisplatin gel infusion. Sur-
gery is generally believed the best treatment option 
for a cure. Surgical resection is recommended for 
patients who have relatively functional livers with 
unifocal tumors (,5 cm). The 5-year overall sur-
vival rate can be increased up to 5-fold in well-
selected patients after surgical resection.9 Liver 
transplantation is another option for treatment of 
early stage HCC. The most commonly used crite-
ria for candidate selection is the Milan criteria pro-
posed by Mazzaferro et al in 1996.10 Patients with 
HCC who either have one tumor (#5 cm) or have 
2 to 3 tumors (#3 cm) could be selected for liver 
transplantation. The 5-year overall survival rate for 
patients who have received liver transplantation is 
up to 70%.11 However, the supply of donor livers 
is quite limited. Therefore, selection of candidates 
becomes more important to ensure the best outcome. 
On the other hand, some surgeons have suggested 
more inclusive parameters than the Milan criteria in 
an effort to benefit more patients.
Unfortunately, patients with HCC are usually 
found to be in the advanced stages at the time of diag-
nosis, which severely limits these surgical options. 
A widely used conventional treatment for patients with 
advanced HCC is chemotherapy. However, response 
rates to such treatments are poor or nonexistent given 
the fact that HCC is a highly aggressive tumor that 
often shows resistance to chemotherapy. Therefore, 
there is an urgent clinical need to develop more effec-
tive therapies for patients with advanced HCC.
Recent discoveries in the molecular mechanisms 
of HCC pathogenesis have created many opportuni-
ties for developing targeted therapies for the treatment 
of advanced HCC. Some key signaling pathways 
have been identified, such as epidermal growth fac-
tor receptor (EGFR) pathway, insulin-like growth 
factor receptor (IGFR) pathway, vascular endothelial 
growth factor (VEGF) pathway, and so on. Target-
ing these molecular pathways provides a potential 
to generate new therapeutic approaches for the treat-
ment of advanced HCC. One successful example is 
the recently FDA approved clinical use of sorafenib, 
a multikinase inhibitor, for patients with advanced 
HCC.12,13 This approval unveils a new era of targeted 
therapy in HCC and encourages more targeted agents 
being developed and tested in the systemic treatment 
of advanced HCC.
In this review, we will focus on some key targets 
relevant to the signaling pathways implicated in HCC 
pathogenesis and evaluate the features of such tar-
geted therapies in clinical trials.
Hcc-Associated Molecular pathways  
and epigenetic Regulation
The occurrence of tumor development in liver 
requires genetic/epigenetic aberrations in normal 
hepatocytes, which could be induced by risk fac-
tors as mentioned above. The malignant transforma-
tion of HCC, which is called hepatogenesis, is a very 
complex and multistep process that may take years 
to develop. The most frequent and direct risk factor 
for HCC is liver cirrhosis, which is mostly developed 
by hepatitis infection and chronic inflammation. The 
pathogenesis of HCC eventually results in certain 
genetic/epigenetic alternations, such as point muta-
tion, chromosomal amplification/deletion, genomic 
instability, gene methylation, and histone deacetyla-
tion, which ultimately lead to the dysregulation of 
Review of targeted therapies for advanced HCC 
Clinical Medicine Insights: Oncology 2013:7 89
many molecular signaling pathways. Generally, the 
activation of  specific oncogenes such as Ras (50% 
of HCCs) and inactivation of specific tumor suppres-
sors such as TP53 (27% of HCCs) lead to the pro-
liferation and survival of HCC cells.14,15 Since HCC 
is a highly genomic heterogeneous solid tumor, mul-
tiple oncogenic signaling pathways can be activated 
simultaneously. As of yet, no single dominant signal-
ing pathway has been found to be specifically altered 
during the pathogenesis of HCC.16 It is therefore rea-
sonable to develop therapeutic treatment for HCC by 
targeting multiple signaling pathways simultaneously 
using a single agent. Disrupted signaling pathways 
that are associated with HCC carcinogenesis are pro-
moting angiogenesis, enhancing growth, and inhibit-
ing apoptosis, all of which can lead to uncontrolled 
growth of tumor cells. The following pathways are 
discussed due to their critical role in the course of 
HCC pathogenesis.
Angiogenesis-related pathways
HCC is characterized as a hypervascular solid tumor 
with a high tendency towards vascular invasion.17 
The angiogenesis in HCC is essential for the tumor 
growth by supplying oxygen and nutrients and is the 
end result of a complex network of orchestrated action 
among tumor cells, endothelial cells, and growth fac-
tors. The major mediator of the angiogenesis in HCC 
is vascular endothelial growth factor (VEGF).18,19 
Circulating VEGF is a key proangiogenic factor 
which binds to its receptors (VEGFR1-3, mainly 2) 
on endothelial cells and induces the dimerization and 
autophosphorylation of the receptor, which activates 
the downstream signal pathway eventually leading to 
angiogenesis (Fig. 1).20 Elevated expression level of 
VEGF has been found in most HCC, which is associ-
ated with poorer prognosis and decreased survival.21 
Apart from VEGF, other growth factors including 
the platelet-derived growth factor (PDGF), fibroblast 
growth factor (FGF), and angiopoietin have been 
shown to make a significant contribution to the angio-
genesis in HCC.22 These growth factors thus appear 
to be attractive antiangiogenesis candidates for tar-
geted therapies.
Growth-related pathways
In addition to increased angiogenesis, dysregulation 
of signaling pathways associated with cell growth 
has also been shown to be critical in the  development 
of HCC (Fig. 1). Molecular aberrations of growth 
pathways are directly involved in cell prolifera-
tion and the pathogenesis of HCC regarding tumor 
growth, invasion, and metastasis. Some key signaling 
pathways are the hepatocyte growth factor receptor 
pathway (HGFR), epidermal growth factor receptor 
(EGFR) pathway, insulin-like growth factor 1 recep-
tor (IGF-1R) pathway, and PI3K/Akt/mTOR pathway. 
Other pathways such as the Wnt-β catenin pathway 
and the hedgehog pathway are implicated in HCC, 
but the therapies targeting these pathways are only in 
their early stages.
HGF/C-Met pathway
HGF is secreted by stellate cells and is an impor-
tant growth factor for liver regeneration and injury 
repair.23 Its receptor is c-Met, a typical receptor 
tyrosine kinase (RTK). Numerous studies have shown 
that the HGF/c-Met signaling pathway is required for 
normal mammalian development and is involved in 
diverse cellular responses such as cell proliferation, 
survival, and differentiation depending on the par-
ticular cell type and the microenvironment. Under 
physiological conditions, the HGF/c-Met pathway 
does not contribute significantly to the liver homeo-
stasis; however, in circumstances of liver removal or 
injury, the pathway is heavily activated as an impor-
tant mediator in the liver regeneration processes.24 
Deregulation and activation of c-Met may result in 
unregulated cell growth and differentiation, thus con-
tributing to malignant transformation. Like many 
other RTK pathways, HGF/c-Met pathway is acti-
vated by the binding of HGF to its receptor c-MET, 
which results in the receptor autophosphorylation 
and the activation of the downstream intracellular 
signaling pathways including the PI3K and mitogen-
activated protein kinase (MAPK) pathways. c-Met 
overexpression or enhanced activation relative to nor-
mal tissues has been noted in many human cancers. In 
HCC, about 20% to 48% of samples from surgical 
specimens showed elevated levels of c-Met, which is 
associated with poor outcome in patients.25 Although 
overexpression of c-Met has been found to correlate 
with the increased malignancy of human HCC, there 
is still lack of understanding regarding the big picture 
of the exact role of this pathway in the pathogenesis 
of HCC.
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eGFR pathway
EGFR, also called ErbB1 and Her1, is a member of 
an RTK family of 4 related receptors, which includes 
ErbB2/Her2/Neu, ErbB3/Her3, and ErbB4/Her4.26 
Every member of this family has some identified 
ligands except ErbB2/Her2/Neu. The most com-
mon ligand for EGFR is epidermal growth factor 
(EGF), but EGFR also binds to other ligands such 
as transforming growth factor α (TGF-α), amphi-
regulin, and β-cellulin.27 Upon binding with its 
ligands, EGFR undergoes receptor homodimeriza-
tion or heterodimerization with ErbB2 or ErbB3, 
resulting in receptor tyrosine kinase activation and 
 autophosphorylation. The main downstream signal-
ing pathways include the PI3K/Akt/mTOR pathway, 
the Ras/Raf/MEK/ERK1/2-MAPK pathways, and 
the signal transducer and activator of transcription 
pathways (STAT 3 and 5). Activation of these path-
ways stimulates cellular division, survival, and apop-
tosis, and any alteration in these pathways aids tumor 
growth and progression.28
IGF-1R pathway
IGF-1R basically has two ligands: IGF-1 and IGF-2. 
Binding of these ligands to a cysteine-rich domain 
in the extracellular α subunit of IGF-1R triggers 
self-dimerization and autophosphorylation of three 
tyrosines in the activation loop of the tyrosine kinase 
domain in the cytoplasmic portion of the β subunit, 
which results in amplification of tyrosine kinase 
activity and further autophosphorylation of addi-
tional tyrosine residues.29 These phosphotyrosine 
containing motifs are binding sites for adaptor and 
effector molecules in receptor signaling pathways. 
Binding of the adaptor protein Shc and the docking 
protein IRS-1 to IGF-1R activates the MAPK and 
PI3/Akt/mTOR signaling pathways, respectively. 
Genetic studies have demonstrated that mice defi-
cient in IGF-1R die during the development; mice 
with only one copy of IGF-1R gene exhibit almost 
half body mass reduction.30–32 IGF-1R pathway plays 
a crucial role in cell proliferation, differentiation, 
and apoptosis.
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Figure 1. Diagram of signaling pathways stimulated by ligand binding to the tyrosine kinase receptor.
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Enhanced expression of IGF-1R and IGF-2 has been 
correlated with disease implication in HCC.33–35 On the 
other hand, IGF binding proteins such as IGFBP-3, which 
regulate the circulating concentration of IGF and IGF 
in the tumor microenvironment, are  downregulated.36 
Further, the expression of IGF-2R, a receptor with a 
relative short intracellular tail, which functions to clear 
IGF-2 from cell surface to attenuate the IGF-1R signal-
ing, is also downregulated in some HCCs.37
IGF-1R has long been a target for the treatment of 
various tumors due to its overexpression on cell sur-
face. Recent evidence shows that IGF-1R undergoes 
nuclear translocation in cancer cells and autoregulates 
its gene expression.38–40 We have further found that 
gefitinib resistant HCC cells have an increased level of 
the IGF-1R nuclear translocation.41 The biological role 
of this nuclear IGF-1R in cancer cells remains unclear; 
thus, nuclear IGF-1R will merit attention when design-
ing future IGF-1R targeted therapies for HCC.
PI3K/Akt/mTOR pathway
The PI3K/Akt/mTOR pathway can be activated by 
many RTK as described above and plays an essential 
role in the cell survival, growth, and  proliferation.42 
Phosphatidylinositol 3 kinase (PI3K) has two  subunits: 
one subunit p85 as the adaptor and another subunit 
p110 as the kinase. When associated with cytoplas-
mic tails of some relevant RTKs, PI3K phosphorates 
phosphatidylinositol 3,4,5-triphosphate (PIP3) to 
generate phosphatidylinositol 4,5-biphosphate (PIP2) 
and activates Akt (also known as protein kinase B, 
PKB) through phosphoinositide-dependent kinase 
(PDK). The PI3K pathway can be suppressed via 
dephosphorylation of PIP3 by phospharase and tensin 
homologue (PTEN).43
The major mediator and regulator of this path-
way is mammalian target of rapamycin (mTOR) 
(Fig. 1). Once activated by PI3K, mTOR promotes 
cell growth and proliferation by stimulating protein 
synthesis through phosphorylation of 4E-BPs and the 
S6 kinases. In addition to receiving signals from Akt, 
mTOR can be directly activated by the cell’s environ-
mental growth factors and nutrients.44 When the cell 
needs additional resources, mTOR can increase nutri-
ent uptake and promote angiogenesis. Further, mTOR 
can increase the activity of Akt and thus enhance the 
effect of this signaling pathway.45
The signaling pathway that includes mTOR is 
highly active in many cancer cells, including HCC.46,47 
Abnormal association of PI3K to RTK or loss of func-
tion of PTEN leads to uncontrolled activation of this 
pathway and causes carcinogenesis. Actually, activa-
tion of the PI3K/Akt/mTOR pathway is associated 
with poor prognosis in many cancers and is linked to 
resistance to many types of therapy.
Other emerging pathways
Apart from the above described signaling pathways 
that are under active clinical trials for targeted thera-
pies in HCC, there are an increasing number of other 
signaling pathways that are found to be involved in 
the pathogenesis of HCC. These pathways include 
the Notch signaling pathway,48 the hedgehog sig-
naling pathway,49 the transforming growth factor β 
(TGF-β) signaling pathway,50,51 and the Wnt-β-catenin 
pathway.52,53 Although these pathways play an impor-
tant role in HCC, drugs targeting these pathways are 
in early stages, and further basic and clinical studies 
are needed before relevant clinical targeted therapies 
can be developed.
epigenetic regulation and microRnA
Despite deregulation of various signaling pathways 
through classic genetic mutations, which either activate 
oncogenes or inhibit tumor suppressor genes, cancer 
development can be triggered by epigenetic mechanisms 
that alter gene expression through DNA modification 
without changing DNA sequences. Generally, there are 
3 types of epigenetic mechanisms: gene methylation/
demethylation, histone acetylation/deacetylation, and 
noncoding RNAs such as microRNAs (Fig. 2).
Gene methylation can occur in the promoter region, 
rich with CpG islands. In cancer cells, tumor suppres-
sor genes are usually silenced due to the hypermethy-
lation of their promoter regions. Methylated promoter 
region inhibits the binding of critical transcriptional 
factors to the gene thus block the transcription. On 
the other hand, some genes such as those involved in 
tumor invasion and metastasis that are supposed to be 
silent under normal physiological condition are acti-
vated in cancer cells, resulting in cancer progression.
DNA methylation has been found to have a close 
connection with chromatin configuration.54,55 While 
unmethylated DNA is usually associated with loose 
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chromatin configuration that is active for gene 
 transcription, methylated DNA is associated with 
tight chromatin configuration that is inactive for gene 
transcription. The state of chromatin configuration is 
regulated by histone acetyltransferases (HATs), which 
add acetyl groups to histone H3 and H4 tails, and his-
tone deacetylases (HDACs), which remove acetyl 
groups from the tails. Methylated DNA can recruit 
HDACs to condense chromatin structure.
microRNAs (miRNAs) are a group of noncoding 
small molecules with 18 to 23 nucleotides in length. 
miRNAs are post-transcriptional gene regulators that 
play crucial roles in almost every normal cellular 
process. Alteration of miRNA levels can cause the 
activation of oncogenes or the inhibition of tumor 
suppressor genes, leading to cellular transformation 
and cancer development. In most cases of cancer, 
miRNAs are usually found to be downregulated.56 
Recent evidence demonstrated that miRNAs can be 
regulated by DNA methylation.57,58
Since aberration of epigenetic regulation is closely 
associated with tumor formation, key enzymes 
involved in these mechanisms such as HATs and 
HDACs have becoming attractive targets of therapeu-
tic treatment for various cancers.59,60
Mechanism of Action, safety, and 
Efficacy of Targeted Therapies in HCC
Agents that specifically disrupt targets in HCC asso-
ciated molecular pathways are designed and tested 
to suppress the development of liver cancer. There 
are basically two types of these agents for advanced 
HCC systemic therapy: small molecule kinase inhibi-
tors and monoclonal antibodies. Some targeted 
therapies based on these agents are summarized in 
Figures 2 and 3. Based on the HCC relevant signaling 
pathways as described above, agents that disrupt these 
pathways are reviewed and discussed in regards to the 
molecular action, efficacy, safety, and metabolism.
Anti-veGFR pathway
Sorafenib
Sorafenib (Nexavar/Bay43-9006, Bayer Pharmaceu-
ticals Corporation, Leverkusen, Germany) is a mul-
titargeted small molecule that inhibits the activity 
of VEGFR, PDGFR, FGF as well as RAF to block 
tumor proliferation and angiogenesis (Fig. 3A and B). 
Sorafenib has demonstrated safety and efficacy against 
a wide variety of cancers in numerous preclinical and 
clinical studies.61
The pharmacokinetic characteristics of sorafenib 
regarding absorption, distribution, metabolism, and 
excretion have been evaluated. The peak plasma 
level of sorafenib occurs around 3 hours after  dosing; 
however, there is no linear relationship between dos-
ing and exposure. The bioavailability of sorafenib is 
reduced when taken with food.62–64 Since sorafenib is 
highly protein bound, it is estimated that there is a 
large volume of distribution. Metabolism of sorafenib 
is about 50%, and this drug is mainly eliminated 
through the liver.63
Sorafenib established itself as an effective drug 
for the treatment of advanced HCC in recent clini-
cal trials.64–66 In two recent, large, randomized, dou-
Methylated DNA
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Demethylated DNA
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Gene transcription
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Extracellular
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miRNAs
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DNA
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Belinostat
Figure 2. Mechanisms of epigenetic regulation in cancer gene expression. 
Abbreviations: HAT, histone acetyltransferase; HDAC, histone deacetylase; miRNA, microRNA; DNMT, mammalian DNA methyltransferase.
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ble-blinded phase III trials, sorafenib improved the 
overall survival (OS).67,68 In one trial, 602  Caucasian 
patients with advanced HCC were recruited and 
evaluated between sorafenib (299 patients) and pla-
cebo (303 patients). The median OS in the sorafenib 
treated group was 10.7 months compared with 
7.9 months in the placebo group. Clearly, sorafenib 
increased OS out of placebo by total 44%. The  hazard 
ratio for sorafenib/placebo was 0.69 based on 321 
deaths. Sorafenib decreased the relative risk of death 
by 31%.67 In another similar trial, 226 Asian-Pacific 
patients with advanced HCC (mostly developed from 
EGF
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Sunitinib
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Ramucirumab
VEGF
Bevacizumab
VEGFR
IGF
IGF-1R
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A
Figure 3. Molecular action of targeted agents in tyrosine kinase receptors and the corresponding signaling pathways. (A) Agents against tyrosine kinase 
receptors or ligands. (B) Agents against targets in signaling pathways.
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hepatitis B infection) were recruited and  evaluated 
between sorafenib (150 patients) and placebo 
(76 patients). The median OS in the sorafenib treated 
group was 6.5 months compared with 4.2 months in 
the placebo group.68 Although tolerance to sorafenib 
was found generally good in these two studies, there 
were treatment-related adverse events. The most 
frequently occurring events were diarrhea, fatigue, 
weight loss, and hand-foot skin reaction.
So far, sorafenib is the only drug shown to improve 
the overall survival in patients with advanced HCC 
and was approved for clinical use by the US Food and 
Drug Administration (FDA) in 2007.12 Other coun-
tries such as European countries and China have also 
approved sorafenib for advanced HCC treatment. 
Sorafenib has thus become the standard of care for 
patients with advanced HCC.
More clinical trials are being tested to evaluate the 
use of sorafenib in combination with other targeted 
agents and conventional treatments such as chemo-
therapy. A finished randomized phase II clinical trial 
reported an overall survival rate of 13.7 months in 
patients treated with the combination of sorafenib 
and doxorubicin compared with 6.5 months in 
patients treated with doxorubicin alone.69 Some 
other agents being tested in combination with 
sorafenib are AVE1642 (NCT00791544), erlotinib 
(NCT00901901), linsitinib (NCT01334710), cixu-
tumab (NCT01008566 and NCT00906373), and tem-
sirolimus (NCT01008917 and NCT01335074).
Sunitinib
Sunitinib (Sutent/SU11248, Pfizer Inc., New York, 
USA) is another oral multikinase inhibitor like 
sorafenib that mainly targets VEGFRs and PDGFRs 
(Fig. 3A). This drug is well studied and has been 
approved for the treatment of renal cell carcinoma 
and gastrointestinal stromal tumors that are refractory 
to imatinib.70
The absorption of sunitinib peaks within 6 to 
12 hours after dosing. Taking the drug with food 
or not has a marginal effect on the exposure.71 Like 
sorafenib, sunitinib is highly protein bound and has a 
large volume of distribution. Sunitinib is metabolized 
by CYP3A4 and is excreted mainly via feces.72
While early clinical trials in patients with advanced 
HCC showed that this drug has encouraging results on 
efficacy and tolerance,73,74 the most recent phase III 
SUN 1170 clinical trial showed that use of sunitinib 
increased serious drug-related adverse events. This 
trial was subsequently discontinued. Thus,  sunitinib 
is no longer tested for the treatment of advanced 
HCC.75
vandetanib
Vandetanib (Zactima/ZD6474, AstraZeneca, Wilmington, 
USA) is an oral tyrosine kinase inhibitor of VEGFR 
(Fig. 3A). This compound also inhibits the activi-
ties of EGFR and the rearranged during transfection 
(RET) tyrosine kinase receptor. Vandetanib has been 
approved by FDA for the treatment of medullary thy-
roid cancer. In the treatment of advanced HCC, van-
detanib was shown to exert inhibitory effects on cell 
proliferation and migration in preclinical models.76 A 
phase II, placebo-controlled clinical trial (69 patients) 
showed limited efficacy and safety in patients with 
advanced HCC. However, it seems further evalua-
tion with a larger population of patients is needed to 
confirm the benefit of vandetanib on HCC. The most 
common adverse effect profile of vandetanib is diar-
rhea and rash.77
Brivanib
Brivanib (BMS-582664, Bristol-Meyers Squibb, 
New York, USA) is an oral selective inhibitor of 
VEGFR and EGFR (Fig. 3A). Brivanib demonstrated 
significant antitumor activity in HCC xenograft mod-
els by decreasing tumor microvessel density and 
increasing apoptosis of tumor cells.78 Brivanib has 
been evaluated as a first line and a second line agent 
in advanced HCC  treatments. As a first line ther-
apy in a phase II clinical trial, brivanib achieved a 
median 10 months OS.79 In a second line therapy after 
prior treatment with sorafenib, the median OS was 
9.8 months. Major drug-related adverse events were 
fatigue, nausea, loss of appetite, diarrhea, and hyper-
tension.80 More clinical trials are currently underway 
to further evaluate the antitumor activity in patients 
with advanced HCC.
Bevacizumab
Bevacizumab (Avastin, Genetech, San Francisco, 
USA and Roche, Basel, Switzerland) is a recombi-
nant humanized monoclonal antibody neutralizing the 
biological activity of VEGF (Fig. 3A).  Bevacizumab 
has been approved for the treatments of colorectal, 
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non-small-cell lung, and breast cancers. It is the first 
antibody against VEGF to be tested in HCC and has 
been evaluated as both single agent and in combina-
tion with other drugs.
A phase II trial including a total of 46 patients with 
locally advanced HCC showed promising results: 
13% of patients showed partial responses and 65% 
of patients obtained disease stabilization for up to 
6 months.81 However, since some patients with severe 
diseases were excluded from this trial, the clinical 
benefit obtained from bevacizumab treatment seems 
only suitable to well-selected patients. Benefit for a 
broad range of patients shown in a large scale study is 
needed to further endorse the activity of bevacizumab 
in advanced HCC. The major drug-related adverse 
event was severe hemorrhagic complications (11%); 
other drug-related adverse events were arterial throm-
bosis (6%) and hypertension (15%).
The combination use of bevacizumab with other 
chemotherapy agents such as gemcitabine, capecit-
abine, and erlotinib has been evaluated in some phase 
II trials and showed moderate clinical benefit with 
reasonable safety.82–84
Ramucirumab
Ramucirumab (IMC-1121B, ImClone Systems Inc., 
New York, USA) is a fully human immunoglobulin 
G1 monoclonal antibody specifically developed to 
bind to the extracellular VEGF-binding domain of 
VEGFR-2 and block the activation of its receptor 
tyrosine kinase and the downstream signaling path-
ways (Fig. 3A).
Ramucirumab was tested in various solid tumors 
including HCC in a phase I trial and showed objective 
antitumor activity with reasonable safety. The most 
frequently reported serious events included hyperten-
sion (13.5%), abdominal pain (10.8%), and anorexia, 
vomiting, headache, and proteinuria (each in 5.4% of 
patients).85
Preliminary data from a phase II study of 42 patients 
with advanced HCC showed that, as a single agent 
in a first-line monotherapy, ramucirumab achieved a 
disease control rate of 50% and a median progres-
sion-free survival (PFS) of 4.3 months.86 Based on 
this positive study, a phase III clinical trial in HCC 
comparing ramucirumab with placebo for the second-
line treatment after sorafenib is underway (Table 1, 
NCT01140347).
Anti-HGF/c-Met pathway
Foretinib
Foretinib (XL880/GSK1363089, GlaxoSmithKline, 
Brentford, United Kingdom) is an oral selective small 
molecule inhibitor of c-Met and VEGFR-2 (Fig. 3A). 
Since overexpression of c-Met in HCC correlates 
well with the progress of this disease,87 it is generally 
anticipated that targeting c-Met using foretinib could 
produce clinical benefit in patients with advanced 
HCC. Evidence supporting this notion is the recent 
observations that cells lacking c-Met expression do 
not respond well to c-Met inhibitor and that foretinib 
exhibits inhibitory effects on angiogenesis, cell pro-
liferation, and tumor metastasis in preclinical HCC 
models.88,89
A phase I/II study in patients with advanced HCC 
is being tested for safety and tolerance of foretinib 
(NCT00920192).
Tivantinib
Tivantinib (ARQ197, ArQule, Inc., Woburn, USA) 
is the first in class orally available selective inhibitor 
of c-Met (Fig. 3A). This is also a novel, non-ATP-
competitive c-Met inhibitor, the most advanced agent 
in a new class of trans-3,4-bisubstituted pyrrolidine-
2,5-diones.90
Results from a phase Ib clinical trial of 21 patients 
with advanced HCC showed antitumor activity with 
progression-free rates at 2 and 4 months of 59.7% and 
39.8%, respectively. The study also found a manage-
able toxicity of tivantinib with anemia (43%), asthenia 
(43%), neutropenia (38%), leukopenia (33%), diar-
rhea (29%), anorexia (29%), and fatigue (24%).91
On the basis of results from the phase Ib study, a 
global, randomized, double-blind, placebo-controlled, 
phase II clinical trial in patients with unresectable 
HCC is currently enrolling patients (NCT00988741).
Anti-eGFR pathway
Gefitinib
Gefitinib (Iressa/ZD1839, AstraZeneca) is the first 
small molecular inhibitor of EGFR tyrosine kinase 
(Fig. 3A). Gefitinib inhibits EGFR tyrosine kinase 
activity by binding to the ATP-binding site of the 
receptor and blocking the Ras signaling pathway.
Gefitinib is developed to treat cancers in which 
EGFR is overexpressed, such as lung cancer and 
breast cancer. Although demonstrated the ability 
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to prevent HCC development in a murine model,92 
when applied to HCC in a phase II clinical trial with 
31 patients enrolled, gefitinib induced a median OS 
of 6.5 months. Since the results did not meet the cri-
terion for the second stage of the study, the authors 
concluded that this drug alone did not exhibit sig-
nificant antitumor activity in patients with advanced 
HCC.93
Our recent study showed that gefitinib resistance in 
HCC cells was associated with IGF-1R nuclear trans-
location and accumulation.41 It seems that nuclear IGF-
1R may play an important role in gefitinib resistance 
in HCC. Inhibiting IGF-1R expression using a specific 
miRNA may help improve the efficacy of gefitinib.
erlotinib
Erlotinib (Tarceva/OSI774, Genetech Inc. and 
Roche) is an oral specific inhibitor of EGFR 
tyrosine kinase (Fig. 3A). Erlotinib shares the com-
mon chemical backbone structure with gefitinib. 
The peak plasma levels occur 4 hours after dosing. 
It is not recommended to take erlotinib with food. 
Like gefitinib, erlotinib is highly protein bound and 
has an extensive distribution in tissues. It is pre-
dominantly metabolized by CYP3A4 and CYP3A5, 
and 91% of the dose of 100 mg was recovered over 
11 days.94,95
As a more potent small molecule compound than 
gefitinib, erlotinib showed antitumor activity in a 
 variety of solid tumors including advanced lung 
 cancer and pancreatic cancer. Two phase II clinical 
studies using erlotinib as the first line therapy were 
conducted in patients with advanced HCC. The 
first trial (38 patients enrolled) reported a median 
OS of 13 months and the PFS at 6 months in 32% 
of patients.96 The second trial (40 patients enrolled) 
reported a median OS of 10.75 months and the PFS 
at 4 months in 43% patients.97 More clinical trials are 
ongoing to evaluate the combination of erlotinib with 
sorafenib and other agents.98
Table 1. Molecular targeted agents used for clinical trials in HCC.*
Agent Classification Target stage Trial identifier
Sorafenib Small molecule compound veGFR, PDGFR, RAF Approved
vandetanib Small molecule compound veGFR, eGFR Phase I/II NCT00496509 
NCT00508001
Brivanib Small molecule compound veGFR, FGFR Phase III NCT00858871 
NCT00825955
Sunitinib Small molecule compound veGFR, PDGFR Phase III NCT00699374
Bevacizumab Monoclonal antibody veGF Phase II NCT00162669
Ramucirumab Monoclonal antibody veGFR Phase II/III NCT00627042 
NCT01140347
Foretinib Small molecule compound c-Met, veGFR Phase I/II NCT00920192
Tivantinib 
(ARQ197)
Small molecule compound c-Met Phase I/II NCT00802555 
NCT00988741
Gefitinib Small molecule compound eGFR Phase II NCT00071994 
NCT00282100
erlotinib Small molecule compound eGFR Phase I/II NCT00047346 
NCT00047333
Lapatinib Small molecule compound eGFR Phase II NCT00107536 
NCT00101036
Cetuximab Monoclonal antibody eGFR Phase II NCT00142428
Linsitinib 
(OSI-906)
Small molecule compound IGF-1R Phase II NCT01101906
Ave1642 Monoclonal antibody IGF-1R Phase I/II NCT00791544
Cixutumumab Monoclonal antibody IGF-1R Phase II NCT00639509
Sirolimus Small molecule compound mTOR Phase II NCT01374750
everolimus Small molecule compound mTOR Phase I/II NCT00390195
Selumetinib 
(AZD6244)
Small molecule compound MeK Phase I/II NCT00550719 
NCT00604721
Belinostat Small molecule compound HDAC Phase II NCT00321594
note: *Information gathered from ClinicalTrials.gov and references.98,123,124
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Some of the major side effects found in a combined 
trial with bevacizumab were fatigue (20%), hyperten-
sion (15%), and gastrointestinal bleeding (12.5%).99
Lapatinib
Lapatinib (Tyverb/GW572016, GlaxoSmithKline) is 
a dual tyrosine kinase inhibitor that blocks EGFR and 
HER2/NEU signaling pathways (Fig. 3A). Lapatinib 
is an orally active small molecule originally designed 
for the treatment of breast cancer with elevated 
expression of EGFR and HER2/NEU.
The pharmacokinetics of lapatinib were reported 
in some studies. The peak plasma concentration could 
be reached within 3 to 4 hours after dosing, and food 
does not significantly reduce its half life.100 Lapatinib 
is highly protein bound, and the volume of distribution 
is large. CYP3A4 is the main metabolizing enzyme of 
lapatinib. Excretion of lapatinib is primarily through 
the liver.101
Although HCC cells usually do not express a 
high level of EGFR and HER2/NEU, lapatinib was 
evaluated in two separate phase II clinical trials. 
In one study, 26 patients with advanced HCC were 
included. The median OS and PFS were 12.6 months 
and 1.9 months, respectively. Ten patients (40% of 
total enrolled) showed stable disease, and 6 patients 
(23% of total enrolled) had stable disease lasting 
more than 120 days. The most common drug-related 
adverse events observed in this trial were diarrhea 
(73%), nausea (54%), and rash (42%).102 In another 
study, a total of 40 patients with advanced HCC were 
tested. The median OS and PFS were 6.2 months and 
2.3 months, respectively. Although tolerance to this 
drug was high, only 5% of patients showed objective 
response. Results from this trial indicated that therapy 
with lapatinib in HCC did not meet the target efficacy 
rate.103
Cetuximab
Cetuximab (Erbitux/IMC-C225, Bristol-Meyers 
Squibb, and Merck Serono, Geneva, Switzerland) is a 
chimeric monoclonal antibody neutralizing the extra-
cellular domain of EGFR from the binding of EGF 
(Fig. 3A). This antibody drug is given by intravenous 
infusion and has been used in treatment of metastatic 
colorectal cancer and head and neck cancer.103,104
Evaluation of cetuximab as a single agent treat-
ment in advanced HCC was tested in two phase II 
clinical trials. The median OS and PFS observed in 
the first trial with 30 patients enrolled were 9.6 months 
and 1.4 months, respectively. Although stable disease 
was found in 17% patients, no clinical responses were 
observed in this study.105 In a similar designed sec-
ond study, 27 patients within the total of 32 enrolled 
were evaluated for efficacy. Again, there were no 
clinical responses. The median PFS was 1.8 months, 
and the stable disease was observed in 44.4% patients 
for 8 weeks.106 In combination with gemcitabine and 
 oxaliplatin (GEMOX), cetuximab was evaluated in 
another phase II clinical trial. The clinical response 
rate was 23%. However, since no data are available 
for cetuximab as a single agent and GEMOX regimen 
showed antitumor activity before, the exact contribu-
tion of cetuximab in this trial remains unknown.107
Anti-IGF-1R pathway
Linsitinib
Linsitinib (OSI-906, OSI Phamaceuticals, Farm-
ingdale, USA) is a novel dual tyrosine kinase inhibitor 
of IGF-1R and insulin receptor (IR) (Fig. 3A). 
Linsitinib is a small molecular compound that specifi-
cally binds to the intracellular domain of IGF-1R and 
IR and blocks the autophosphorylation of the recep-
tors and the downstream signaling pathways.108
A phase II clinical trial was initiated to evalu-
ate its efficacy and safety in patients with advanced 
HCC as a second line of therapy for HCC refractory 
to a first line sorafenib therapy (NCT01101906). 
 Unfortunately, the company recently announced the 
termination of this trial.
Ave1642
AVE1642 (Sanofi-Aventis, Paris, France) is a human-
ized monoclonal antibody that specifically blocks 
IGF-1R signaling by binding to the extracellular 
domain (Fig. 3A).
A phase I clinical trial reported that AVE1642 can 
be safely combined with active doses of sorafenib in 
patients with advanced HCC. This combination did 
not interfere the pharmacokinetics of either AVE1642 
or sorafenib at the concentrations tested and achieved 
a mean PFS of 13.3 weeks in most patients.109
Cixutumumab
Cixutumumab (IMC-A12, ImClone System Inc.) 
is also a humanized monoclonal antibody that 
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specifically neutralizes the extracellular IGF-1 bind-
ing domain of IGF-1R and inactivates the subsequent 
signaling pathways (Fig. 3A).
Preclinical data showed that cixutumumab blocks 
proliferation, induces apoptosis, and delays tumor 
growth both in vitro and in vivo.110 A recent phase II 
clinical trial in 22 patients with advanced HCC showed 
that a median OS was 8 months, and 7 patients (29% 
of total) had stable disease for at least 4 months. 
 However, the study concluded that  cixutumumab 
had no antitumor activity as a single agent in HCC, 
although an initial phase I study reported partial 
activity.111,112
Recent research progress may explain the lack of 
activities of antibody drugs targeting IGF-1R in clini-
cal trials. IGF-1R has been found to migrate and accu-
mulate in cancer cell nuclei, and drug-resistant cancer 
cells have increased levels of nuclear IGF-1R.38–41 
It seems that direct inhibition of the expression of 
IGF-1R in cancer cells might improve the antitumor 
activity and cancer drug sensitivity. Nuclear IGF-1R 
should be considered in the future design of IGF-1R-
based targeted therapies.
Anti-mTOR pathway
Sirolimus and everolimus
Sirolimus and everolimus (RAD001, Novartis, Basel, 
Switzerland) are analogues of rapamycin and selective 
inhibitors of mTOR kinase (Fig. 3B). Since mTOR 
plays a pivotal role in signal transduction of many 
receptor tyrosine kinase induced signaling pathways, 
inhibiting mTOR should have the antitumor activity 
for a broad range of cancer stimuli.
Experimental studies using this rapamycin and 
its analogue everolimus (RAD001) in HCC cells 
showed significant effects in reducing tumor cell 
growth and improving cell survival.113,114 One recent 
phase I/II study in 28 patients with advanced HCC 
showed everolimus had clinical activity with a 
median OS of 8.4 months.115 Promising results on the 
efficacy in patients with advanced HCC were also 
reported from two pilot clinical trials using sirolimus. 
The first study, with 21 patients enrolled, showed a 
median OS of 6.5 months and stable disease for at 
least 3 months in 24% of patients.112 The second study, 
with 14 patients enrolled, observed a complete clini-
cal response in 7% of patients and partial response in 
33% of patients. In addition, sirolimus demonstrated 
a safe profile because no major drug-related adverse 
events were observed in these studies.116
Several ongoing trials are currently recruiting 
patients with advanced HCC to determine the com-
binational effects of these drugs with sorafenib and 
conventional chemotherapeutic agents.
It is worth noting that cancer drug sensitivity can 
be improved in patients with certain gene mutations. 
For example, a recent study, using the whole genome 
sequencing technology, identified loss of function 
mutations in tuberous sclerosis complex 1 (TSC1), 
a regulator of mTOR pathway activation. Patients 
with the TSC1 gene mutations in bladder tumors 
showed an increased everolimus sensitivity and bet-
ter outcomes.117
Anti-MeK/eRK pathway
Selumetinib
Selumetinib (AZD6244/ARRY-142886, AstraZeneca) 
is an orally active new inhibitor that binds to MEK to 
block the RAF/MEK/ERK pathway, which appears 
to be the most significant signaling pathway in HCC 
development (Fig. 3B).
Selumetinib showed significant antitumor activity 
both in vitro with HCC cells and in vivo with xeno-
grafts.118 However, when tested in a phase II study in 
19 patients with advanced HCC, selumetinib failed to 
exhibit convincing antitumor activity.119 Results from 
this clinical trial suggest that inhibition of RAF/MEK/
ERK pathway using selumetinib as a single agent in 
the treatment of HCC is not effective.
Combinational use of selumetinib with other agents 
is under active evaluation in separate clinical trials.
Anti-epigenetic regulation
Belinostat
Belinostat (PXD101, Spectrum Pharmaceuticals, 
Irvine, USA) is a small compound inhibitor of HDAC 
(Fig. 2). In a preclinical study with 3 HCC cell lines, 
belinostat showed inhibitory effects on cell growth on 
a dose-based manner and provided the basis for fur-
ther clinical trials.120
In a multicenter phase I/II clinical trial, belinos-
tat was tested in patients (18 in phase I and 42 in 
phase II) with unresectable HCC and chronic liver 
disease. The pharmacokinetics of belinostat demon-
strated a linear relationship from 600 to 1400 mg/m2 
with no significant accumulation. When used with a 
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1400 mg/m2 dose in the phase II study, the stable dis-
ease rate was 45.2%. Among patients whose tumors 
expressed high levels of RAD23B, 58% achieved dis-
ease stabilization compared with 14% of those with 
low RAD23B expression in their tumors. Further, the 
median OS and PFS obtained from this trial were 6.6 
and 2.64 months, respectively.121
This clinical trial suggested that belinostat can 
safely stabilize unresectable HCC. Furthermore, the 
expression level of RAD23B may be eventually used 
as a biomarker for belinostat clinical response and as 
a helpful guide for a personalized medicine approach 
for HCC treatment.122
conclusion
Targeted therapies that specifically block tumor-
 associated signaling pathways using either small 
molecular compounds or humanized monoclonal 
antibodies to inhibit angiogenesis and tumor growth 
represent a new trend of promising novel treatments 
of HCC. The success of sorafenib in the treatment of 
patients with advanced HCC has established sorafenib 
as a new standard of care for patients with advanced 
HCC and encourages a number of novel agents being 
tested in clinical trials. Results of pharmacokinetics, 
safety, and efficacy obtained from those finished and 
ongoing trials will definitely provide valuable infor-
mation for the future improvement of the targeted 
therapies in HCC.
While use as a single agent for the first-line therapy 
may not display full benefits to patients, sorafenib is 
being tested with either another targeted agent or con-
ventional treatments such as chemotherapy and surgery 
as the second-line therapy. More clinical trials are thus 
needed for those emerging novel agents both as single 
agents and in combination with other therapies.
The design of targeted therapies is primary based 
on our understanding at the molecular level of the 
relationship between signaling pathways and the 
 disease. Given the fact that HCC is highly heteroge-
neous and no dominant signaling pathway has been 
found so far, more investigations are warrant in the 
future to elucidate the molecular pathogenesis of this 
disease and the underlying mechanisms.
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